Donate to Illuminate Contact TSF
Visit us on Facebook Visit us on Twitter Visit us on YouTube Visit us on Instagram Visit us on Linkedin Visit us on Tiktok

Choose Your Language:


Posted by: The Sumaira Foundation in News & Announcements

December 22, 2023 — The Sumaira Foundation is pleased to announce the first round of awardees of TSF’s 2023 research grants. Congratulations to all the researchers who will each be awarded with up to $25,000 to initiate their projects!

NMOSD & MOGAD in Montenegro: Clinical Aspects, Pain and Community Impact

Principle Investigator | Sanja Gluscevic, MD, PhD

Institution | Clinical Centre of Montenegro, Neurology Clinic, University of Montenegro

Aim | To provide a comprehensive understanding of NMOSD and MOGAD in Montenegro, with a focus on clinical aspects, pain, and the impact on the community.

Award Amount | $5,000 (This grant was made possible with support from Terry & Greg Clark of The Dorchester Foundation)

A New in Vitro Human Model to Study MOGAD Physiopathology: The MOGAXON Project

Principle Investigators | Álvaro Cobo-Calvo, MD, PhD and Juan Antonio García León

Institutions | Multiple Sclerosis Center of Catalonia (CEMCAT), Vall d’Hebron and University of Malaga (Spain)

Aim | To establish a new in vitro human model comprising an all-human induced pluripotent stem cells (hiPSC)-derived oligodendrocytes co-cultured with neurons that could serve as the bases to reveal new MOGAD-specific mechanisms, a previous essential step before developing novel therapeutic strategies.

Award Amount | $25,000

Latin American Consensus Recommendations for Management & Treatment of Adult MOGAD Patients in Clinical Practice

Principle Investigator | Edgar Carnero Contentti, MD MSc

Institution | Hospital Alemán (Argentina)

Aim | To review how adult patients living with MOGAD should be managed and treated in Latin America in order to improve long-term outcomes and to optimize resources in these populations.

Award Amount | $5,000 (This grant was made possible with support from Terry & Greg Clark of The Dorchester Foundation)

Hyperreflective Foci (HRF): A New Retinal Marker in NMOSD & MOGAD?

Principle Investigators | Joachim Havla, MD and Jonathan A. Gernert, MD

Institution | Institute for Clinical Neuroimmunology, University Hospital LMU Munich (Germany)

Aim I | To conduct a cross-sectional comparison of the number of HRF in eyes without a history of optic neuritis between patients with NMOSD, MOGAD and other demyelinating diseases.

Aim II | To conduct a longitudinal analysis of the number of HRF between patients with NMOSD, MOGAD and other demyelinating diseases considering clinical and imaging follow-up data.

Award Amount | $25,000

Validating the TRIPS-A Scoring Tool for Relapse Prediction in MOGAD

Principle Investigator | Ahmed Obeidat, MD, PhD

Institution | Medical College of Wisconsin (United States)

Aim I | To develop and apply a scoring tool to predict subsequent relapses after an initial attack in people with myelin oligodendrocyte glycoprotein antibody disease.

Aim II | To compare serum levels of neurofilament light (NfL), a marker of neuroaxonal damage, cross-sectionally, between patients falling into the high score category (potentially relapsing) versus those falling into the lower score category (potentially monophasic).

Award Amount | $25,000

Double Seronegative NMO in Latin America: An Epidemiological Overview

Principle Investigators | Ricardo Alonso, MD, Lorna Galleguillos, MD and Carlos Navas, MD

Institutions | Hospital Ramos Mejias (Argentina), Clínica Alemana de Santiago (Chile) and Clínica Colombia (Colombia)

Aim |

Award Amount | $25,000

Thymic Negative Selection in T-cell Repertoire Development in MOG CNS Autoimmunity

Principle Investigator | Scott Zamvil, MD, PhD

Institution | University of California, San Francisco (United States)

Aim I | To evaluate the role of thymic MOG expression in development of the pathogenic T-cell repertoire in MOG-targeted CNS autoimmunity

Aim II | To breed our new MOGfl/fl mice with Foxn1-cre mice to generate mice deficient in thymic expression of MOG (Foxn1-cre-MOGfl/fl) and to confirm selective thymic deficiency.

Award Amount | $25,000

Industry Partners

Community Partners

WARNING: Internet Explorer does not support modern web standards. This site may not function correctly on this browser and is best viewed on Chrome, Firefox or Edge browsers. Learn More.